BSc(Med) MBBS(Hons 1), PhD(UNSW), FRANZCO
Consultant Eye Surgeon
Dr John Chang is the founding director of Strathfield Eye Surgery. He is a highly skilled and experienced ophthalmologist who provides holistic, patient-centred eye specialist care.
Dr Chang always strives for the highest standard of medical and surgical treatment. He takes great care in listening to his patients and taking that extra time so that they obtain a personalised understanding of their diagnosis and treatment options.
Dr Chang specialises in complex cataract surgery in eyes with macular degeneration, diabetic retinopathy, glaucoma or uveitis. Such patients require highly individualised treatment plans that may include intraocular anti-VEGF injection therapy, retinal laser, intravitreal slow-release steroid implant, or micro-invasive glaucoma surgery (MIGS).
Dr John Chang with one of his mentors, Dr Tim Henderson (ophthalmologist), visiting remote indigenous communities in the Northern Territory by plane to provide essential specialist eye care.
Dr Chang is a clinician-scientist with a PhD in ocular immunology in addition to his clinical qualifications as an eye surgeon.
He has had extensive training both in Australian and abroad including international subspecialist training in medical retina and uveitis. It is this strong background in academic rigour and pursuit of knowledge that drives Dr Chang’s ethos of delivering eye care of the highest standard for his patients. He keeps up to date with the latest knowledge and technology to provide the best possible care that is backed up by research data.
Dr Chang has been awarded highly competitive research grants for his work and has been involved as an investigator on various national and international clinical trials in the treatment of macular degeneration and diabetic retinopathy. He has been actively contributing to the progress of medical knowledge on a global scale by presenting at conferences and authoring peer-reviewed research journal publications every year, for more than the past 15 years.
Dr Chang completed RANZCO specialist ophthalmology training in Australia, including at the major teaching hospitals in Sydney, Adelaide and Fred Hollows Foundation outreach eye services in Central Australia.
Dr Chang is a clinical adjunct lecturer at the University of New South Wales and is a member of specialist groups such as the Australian & New Zealand Society of Retina Specialists and Uveitis Special Interest Group.
Dr Chang has been the recipient of multiple NHMRC grants and scholarships for his research as well as academic prizes during his medical and specialist training.
View and search this comprehensive list of Dr Chang's publications in medical journals.
Liu E, Kaidonis G, Gillies MC, Abhary S, Essex RW, Chang JH, Pal B, Daniell M, Lake S, Gilhotra J, Petrovsky N, Hewitt AW, Jenkins A, Lamoureux EL, Gleadle JM, Burdon KP, Craig JE. Mitochondrial haplogroups are not associated with diabetic retinopathy in a large Australian and British Caucasian sample. Sci Rep. 2019 Jan 24;9(1):612. doi: 10.1038/s41598-018-37388-8.
Graham PS, Kaidonis G, Abhary S, Gillies MC, Daniell M, Essex RW, Chang JH, Lake SR, Pal B, Jenkins AJ, Hewitt AW, Lamoureux EL, Hykin PG, Petrovsky N, Brown MA, Craig JE, Burdon KP. Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. BMC Med Genet. 2018 May 8;19(1):71. doi: 10.1186/s12881-018-0587-8.
Whist E, Symes RJ, Chang JH, Chowdhury V, Lim L, Grigg JR, Lin M, Karaconji T, Giblin M, Lim L, McCluskey PJ. Uveitis triggered by treatment for malignant melanoma: A case series. Retinal Cases and Brief Reports (in press).
Graham PS, Kaidonis G, Abhary S, Gillies MC, Daniell M, Essex RW, Chang JH, Lake SR, Pal B, Jenkins AJ, Hewitt AW, Lamoureux EL, Hykin PG, Petrovsky N, Brown MA, Craig JE, Burdon KP. Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. BMC Med Genet. 2018 May; 19(1): 71
Hui MM, Wakefield D, Patel I, Cvejic E, McCluskey PJ, Chang JH. Visual Functioning and Health-related Quality-of-Life are Compromised in Patients with Uveitis. Ocul Immunol Inflamm. 2017 Aug; 25(4): 486-491
Kaidonis G, Craig JE, Gillies MC, Abhary S, Essex RW, Chang JH, et al. Promoter polymorphism at the tumour necrosis factor/lymphotoxin-alpha locus is associated with type of diabetes but not with susceptibility to sight-threatening diabetic retinopathy. Diab Vasc Dis Res. 2016 Mar;13(2):164-7
Kaidonis G, Gillies MC, Abhary S, Liu E, Essex RW, Chang JH, et al. A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetol. 2016 Aug;53(4):643-50.
Burdon KP, Fogarty RD, Shen W, Abhary S, Kaidonis G, Appukuttan B, Hewitt AW, Sharma S, Daniell M, Essex RW, Chang JH, Klebe S, Lake SR, Pal B, Jenkins A, Govindarjan G, Sundaresan P, Lamoureux EL, Ramasamy K, Pefkianaki M, Hykin PG, Petrovsky N, Brown MA, Gilles MC, Craig JE. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia 2015; 58(10): 2288-97.
Kaidonis G, Burdon KP, Gilles MC, Abhary S, Essex RW, Chang JH, Pal B, Pefkianaki M, Daniell M, Lake S, Petrovsky N, Hewitt AW, Jenkins A, Lamoureux EL, Gleadle JM, Craig JE. Common sequence variation in the VEGF-C gene is associated with diabetic retinopathy and diabetic macular oedema. Ophthalmology 2015; 122(9): 1828-36.
Kaidonis G, Abhary S, Daniell M, Gilles M, Fogarty R, Petrovsky N, Jenkins A, Essex R, Chang JH, Pal B, Hewitt AW, Burdon K, Craig JE. Genetic study of diabetic retinopathy: recruitment methodology and analysis of baseline characteristics. Clin Experiment Ophthalmol 2014; 42(5): 486-93.
Chang JH, Mills RA, Pater J, Crompton JL. Case series of cat scratch-inflicted full-thickness corneal lacerations and a review of the literature. Clinical & Experimental Ophthalmology 2012 Mar 7. doi: 10.1111/j.1442-9071.2012.02783.x.
Chang JH, Jang JD, Jamieson RV, Grigg JR. Long-term follow-up study of autosomal dominant optic atrophy in an Australian population. Asia-Pacific Journal of Ophthalmology March/April 2012; 1(2): 88-90.
Karampelas M, Kopsachilis N, Chang JH, Pal B. [Intravitreal bevacizumab for choroidal neovascularisation in a patient with Membranoproliferative Glomerulonephritis Type II] Der Ophthalmologe [article in German] Ophthalmologe. 2012 Aug;109(8):791-3.
Chang JH, Landers J, Henderson TR, Craig JE. Prevalence of uveitis in indigenous populations presenting to remote clinics of Central Australia: the Central Australian Ocular Health Study. Clinical & Experimental Ophthalmology 2012; 40(5): 486-93.
Chui JJ, Li MW, Di Girolamo N, Chang JH, McCluskey PJ, Wakefield D. Iris pigment epithelial cells express a functional LPS receptor complex. Investigative Ophthalmology & Visual Science 2010; 51(5): 2558-67. Epub 2009 Dec 17
Chang JH, McCluskey PJ, Missotten T, Ferrante P, Jalaludin B, Lightman SL. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: Does their use increase anterior uveitis and cystoid macular edema? Br J Ophthalmology 2008; 92 (7): 916-921
Sallam A, Comer RM, Chang JH, Grigg JR, Andrews R, McCluskey PJ, Lightman S. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 2008; 126 (2): 200-205
Chang JH, Hampartzoumian T, Everett E, Lloyd A, McCluskey PJ, Wakefield D. Changes in Toll-like receptor (TLR)-2 and TLR4 expression and function but not polymorphisms are associated with acute anterior uveitis. Investigative Ophthalmology & Visual Science 2007; 48(4): 1711-1717
Chang JH, McCluskey P, Wakefield D. Expression of toll-like receptor 4 and its associated lipopolysaccharide receptor complex by resident antigen presenting cells in the human uvea. Investigative Ophthalmology & Visual Science 2004; 45(6): 1871-1878